Last10K.com

Respirerx Pharmaceuticals Inc. (RSPI) SEC Filing 10-Q Quarterly report for the period ending Monday, September 30, 2019

Respirerx Pharmaceuticals Inc.

HISTORY TOOLS
CIK: 849636 Ticker: RSPI
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2019
Nov. 15, 2019
Document And Entity Information  
Entity Registrant NameRespireRx Pharmaceuticals Inc. 
Entity Central Index Key0000849636 
Document Type10-Q 
Document Period End DateSep. 30, 2019 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Entity Reporting Status CurrentYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Business Flagtrue 
Entity Emerging Growth Companyfalse 
Entity Ex Transition Periodfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 4,045,073
Document Fiscal Period FocusQ3 
Document Fiscal Year Focus2019 

View differences made from one quarter to another to evaluate Respirerx Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Respirerx Pharmaceuticals Inc..

Continue

Assess how Respirerx Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Stockholders' Deficiency (Parenthetical)
Condensed Consolidated Statements Of Stockholders' Deficiency (Unaudited)
Business
Business (Details Narrative)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Commitments And Contingencies (Tables)
Commitments And Contingencies - Summary Of Principal Cash Obligations And Commitments (Details)
Notes Payable
Notes Payable (Details Narrative)
Notes Payable (Tables)
Notes Payable - Schedule Of Convertible Notes Payable (Details)
Notes Payable - Schedule Of Convertible Notes Payable (Details) (Parenthetical)
Notes Payable - Summary Of Note Payable To Related Party (Details)
Organization And Basis Of Presentation
Related Party Transactions
Settlement And Payment Agreements
Settlement And Payment Agreements (Details Narrative)
Stockholders' Deficiency
Stockholders' Deficiency (Details Narrative)
Stockholders' Deficiency (Tables)
Stockholders' Deficiency - Schedule Of Exercise Prices Of Common Stock Options Outstanding And Exercisable (Details)
Stockholders' Deficiency - Schedule Of Exercise Prices Of Common Stock Warrants Outstanding And Exercisable (Details)
Stockholders' Deficiency - Schedule Of Warrants Activity (Details)
Stockholders' Deficiency - Summary Of Stock Option Activity (Details)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Summary Of Significant Accounting Policies - Summary Of Fair Value Of Option Estimated Using Black-Scholes Pricing Model With Valuation Assumptions (Details)

Material Contracts, Statements, Certifications & more

Respirerx Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: RSPI
CIK: 849636
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-19-018014
Submitted to the SEC: Tue Nov 19 2019 5:04:27 PM EST
Accepted by the SEC: Tue Nov 19 2019
Period: Monday, September 30, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/rspi/0001493152-19-018014.htm